Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023GlobeNewsWire • 04/20/23
Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational ProgressGlobeNewsWire • 03/07/23
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023GlobeNewsWire • 02/15/23
Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSsGlobeNewsWire • 12/21/22
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022GlobeNewsWire • 12/12/22
Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life SciencesGlobeNewsWire • 12/08/22
Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysisGlobeNewsWire • 12/08/22
Autolus Therapeutics: Near-Term Catalyst Plus Several Bio Deals Could Shift MomentumSeeking Alpha • 11/16/22
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022GlobeNewsWire • 11/03/22
Autolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational ProgressGlobeNewsWire • 11/03/22
Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022GlobeNewsWire • 10/21/22
Moderna exercises option to license proprietary targeting technology from AutolusGlobeNewsWire • 10/12/22
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus' Proprietary Safety Switch SystemGlobeNewsWire • 10/04/22
Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/08/22
Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022GlobeNewsWire • 07/21/22